Recent studies of sunitinib (Sutent) in patients with metastatic renal cell carcinoma have demonstrated it is effective in prolonging disease control and survival. The FDA-approved dosing regimen for Sutent is 50 mg per day orally for four weeks, followed by a 2-week rest period off of medication (the 4/2 regimen). CORT is conducting a study comparing a continuous dosing regimen of Sutent (37.5 mg per day orally, without treatment interruption) compared to standard dosing with the 4/2 regimen. The study will determine which regimen has superior outcomes and which has the least toxicity (side effects).
The risks of treatment on this study are fatigue, anemia, nausea, vomiting, diarrhea, proteinuria (protein in the urine), delayed wound healing, bleeding, or thrombosis.
For more information on our research studies, visit www.CORTPA.com, or speak with a Study Coordinator at 972-566-5588.
Tags: kidney cancer, metastatic renal cancer, Renal Cancer, renal cell carcinoma, sunitinib, Sutent
